Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Peking Union Medical College Hospital, Center of Excellence in Tissue Engineering Chinese Academy of Medical Sciences, Beijing, China. China.
Curr Mol Pharmacol. 2016;9(4):289-299. doi: 10.2174/1874467208666150928153758.
Mesenchymal stem cells (MSCs) represent a new therapeutic paradigm for a number of diseases because they possess unique biological characteristics such as multipotency, immunomodulation and production of cytokines. Currently, 425 MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy of MSCs. Here, we provide an overview of the clinical status of MSCs by searching the public clinical trials database http://clinicaltrials.gov. Particularly, the role of MSCs in clinical trials to treat bone defects and injuries is highlighted.
间充质干细胞（MSCs）因其具有多能性、免疫调节和细胞因子产生等独特的生物学特性，代表了许多疾病的一种新的治疗范例。目前，已经进行了 425 项基于 MSC 的临床试验，至少针对 12 种病理状况，许多已完成的试验表明 MSC 的安全性和有效性。在这里，我们通过搜索公共临床试验数据库 http://clinicaltrials.gov 来概述 MSC 的临床状况。特别强调了 MSC 在治疗骨缺损和损伤的临床试验中的作用。
